Gene therapy is a promising approach to treat various diseases by introducing or modifying genes in the cells of the patient. However, gene therapy faces many challenges, such as finding the right gene targets, delivering the genes safely and efficiently, and monitoring the effects of gene therapy over time. To overcome these challenges, researchers need to use animal models that closely resemble human physiology and genetics. Nonhuman primates (NHPs) are ideal candidates for this purpose, as they share many similarities with humans in terms of anatomy, immunology, and gene expression.
NHPs are a diverse group of animals that belong to the order Primates, which includes humans. These NHPs have several advantages over other animal models for gene therapy research:
- They have a high degree of genetic similarity with humans, ranging from 93% to 99% depending on the species. This means that they can express human genes more accurately and faithfully than other animals.
- They have a complex immune system that can mount both innate and adaptive responses to foreign antigens. This allows researchers to evaluate the safety and efficacy of gene therapy vectors and products in NHPs before testing them in human trials.
- They have a large brain size and sophisticated cognitive abilities that enable them to perform various behavioral tasks. This enables researchers to assess the impact of gene therapy on neurological functions and disorders in NHPs.
Techniques for Studying Gene Therapy Targets in Nonhuman Primates
To study gene therapy targets in NHPs, researchers need to use techniques that can deliver therapeutic genes to the desired cells and tissues, and monitor the progress of gene therapy over time. Some of the most widely used techniques are:
Use of viral vectors to deliver therapeutic genes to nonhuman primates
Viral vectors are modified viruses that can carry foreign genes into the cells of the host organism. Viral vectors have several advantages for gene therapy, such as high efficiency, specificity, and stability. However, viral vectors also pose some risks, such as immune reactions, toxicity, and insertional mutagenesis. Therefore, researchers need to carefully select and optimize the viral vectors for each gene therapy target and NHP species. Some of the most commonly used viral vectors for gene therapy in NHPs are:
- Adenoviral vectors: These are derived from adenoviruses that cause respiratory infections in humans and animals. Adenoviral vectors can transduce both dividing and non-dividing cells, and can carry large payloads of up to 36 kb. However, adenoviral vectors are highly immunogenic and transient, meaning that they elicit strong immune responses and lose their expression over time.
- Retroviral vectors: These are derived from retroviruses that integrate their genetic material into the host genome. Retroviral vectors can transduce only dividing cells, and can carry small payloads of up to 8 kb. However, retroviral vectors are stable and persistent, meaning that they maintain their expression for a long time. Retroviral vectors include lentiviral vectors (derived from HIV) and gammaretroviral vectors (derived from murine leukemia virus).
- Adeno-associated viral vectors: These are derived from adeno-associated viruses that depend on co-infection with adenoviruses or herpesviruses for replication. Adeno-associated viral vectors can transduce both dividing and non-dividing cells, and can carry medium payloads of up to 5 kb. Adeno-associated viral vectors are less immunogenic and more stable than adenoviral vectors, but less persistent than retroviral vectors.
Nonhuman primates are used in gene therapy drug target validation to study the safety and efficacy of gene therapy treatments before they are tested in humans. Since nonhuman primates share biological similarities with humans, they can provide valuable data on the potential effects of gene therapy treatments and help identify any potential risks or side effects. This helps to ensure that the treatments are safe and effective before they are tested in human clinical trials.
